$1.64
+0.14 (+9.33%)
Open$1.51
Previous Close$1.50
Day High$1.68
Day Low$1.51
52W High$3.92
52W Low$2.47
Volume—
Avg Volume246.5K
Market Cap244.37M
P/E Ratio—
EPS$0.18
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+168.3% upside
Current
$1.64
$1.64
Target
$4.40
$4.40
$2.36
$4.40 avg
$4.89
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 116.39M | 123.33M | 94.21M |
| Net Income | 12.19M | 12.43M | 9.10M |
| Profit Margin | 10.5% | 10.1% | 9.7% |
| EBITDA | 16.58M | 20.40M | 14.08M |
| Free Cash Flow | 11.50M | 12.12M | 8.26M |
| Rev Growth | -3.2% | +20.3% | +7.0% |
| Debt/Equity | 0.59 | 0.58 | 0.64 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |